Scientific publications of interest
Development, calibration and validation of a novel human ventricular myocyte model in health, disease and drug block. Tomek et al. 2019
Impact of disease state on arrhythmic event detection by action potential modelling in cardiac safety pharmacology. Christophe & Crumb, 2019
Improving the in silico assessment of proarrhythmia risk by combining hERG (human ether-à-go-go-related gene) channel- drug binding kinetics and multichannel pharmacology. Li et al, 2017
Am I or am I not proarrhythmic ? Comparison of various classifications of drug TdP propensity. Wisniowska & Polak, 2017
Early assessment of pro-arrhythmic risk of drugs using the in vitro and single cell based in silico models: proof of concept. Abbasi et al, 2017
Evolution of strategies to improve preclinical cardiac safety testing. Gintant G et al., 2016
Comprehensive in vitro proarrythmia assay (CiPA): pending issues for successful validation and implementation. Cavero et al., 2016
Recent developments in using mechanistic cardiac modelling for drug safety evaluation. Davies et al, 2016
A new perspective in the field of cardiac safety testing through the comprehensive in vitro proarrhythmia assay paradigm. Fermini B et al., 2015
In silico study of transmural dispersion of repolarization in non-failing human ventricular myocytes: contribution to cardiac safety pharmacology. Christophe, 2015
CiPA: ongoing testing, future qualification procedures and pending issues. Cavero & Holzgrefe, 2015
Comprehensive in vitro Proarrhythmia Assay, a novel in vitro/in silico paradigm to detect ventricular proarrhythmic liability: a visionary 21st century initiative. Cavero & Holzgrefe, 2014
Simulation of early-after depolarisation in non-failing human ventricular myocytes: can this help cardiac safety pharmacology ? Christophe, 2013
Revolution dawning in cardiotoxicity testing. Chi KR, 2013
Evaluation of an in silico cardiac safety assay: using ion channel screening data to predict QT interval changes in the rabbit ventricular wedge. Beattie KA, 2013
Application of cardiac electrophysiology simulations to proarrhythmic safety testing. Mirams GR & al, 2012
Ions, equations and electrons: the evolving role of computer simulations in cardiac electrophysiology safety evaluations . Gintant G, 2012
Is it time for in silico simulation of drug cardiac side effect ? Mirams GR & Noble D, 2011
Modeling and simulation of preclinical cardiac safety: towards an integrative framework . Soubret A & al, 2009
Using computational modeling to predict arrhythmogenesis and antiarrhythmic therapy. Moreno JD & Clancy CE, 2009
No links